MariMed Q4 revenue beats estimates

Marimed

11/03/2026 21:22

Overview

US cannabis operator's Q4 revenue rose, beating analyst expectations

Q4 adjusted EBITDA missed analyst expectations

2025 wholesale revenue increased 11%

Outlook

MariMed expects growth from adult-use cannabis sales in Delaware throughout 2026

Company sees additional revenue from brand distribution in Maine and new Ohio dispensary

MariMed aims to protect margins and maintain strong liquidity amid sector volatility

Result Drivers

WHOLESALE GROWTH - Co said 2025 wholesale revenue rose 11% and distribution expanded to 85% of dispensaries in core markets

PRICING PRESSURE - Co stated continued pricing pressure across many cannabis markets in the year

Company press release: ID:nGNX5s6T4n

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$41.7 mln
$40.60 mln (3 Analysts)
Q4 Adjusted Net Income
Beat
$2.2 mln
-$3.18 mln (2 Analysts)
Q4 Net Income
-$4.6 mln
Q4 Adjusted EBITDA
Miss
$4.4 mln
$5.12 mln (3 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the drug retailers peer group is "buy"

Wall Street's median 12-month price target for MariMed Inc is $0.17, about 102.8% above its March 10 closing price of $0.08

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)